Immediate Impact

61 hit
Sub-graph 1 of 24

Citing Papers

Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
2025 Hit
A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers
2024 Hit
6 intermediate papers

Works of Dan-Arin Silasi being referenced

SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression
2017
Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFcchimeric protein targeting tissue factor
2011

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Dan-Arin Silasi 80 44 38 38 33 7 186
Patricia Evans 57 0.7× 97 2.2× 8 0.2× 88 2.3× 31 0.9× 7 291
Lipai Chen 115 1.4× 129 2.9× 9 0.2× 51 1.3× 27 0.8× 9 291
Andrea Lindgren 41 0.5× 41 0.9× 15 0.4× 41 1.1× 4 0.1× 11 167
Emad Ibrahim 65 0.8× 49 1.1× 13 0.3× 8 0.2× 15 0.5× 8 147
Kailas Munot 104 1.3× 117 2.7× 7 0.2× 7 0.2× 51 1.5× 8 271
Joanne E. Anstee 107 1.3× 135 3.1× 16 0.4× 7 0.2× 6 0.2× 7 277
Alexandra H. Besser 114 1.4× 123 2.8× 3 0.1× 21 0.6× 42 1.3× 6 283
Koen M. Marien 60 0.8× 61 1.4× 2 0.1× 32 0.8× 23 0.7× 11 160
Sheila Hodgson 122 1.5× 38 0.9× 2 0.1× 31 0.8× 40 1.2× 8 245
Roya Behrouzi 30 0.4× 46 1.0× 6 0.2× 39 1.0× 3 0.1× 11 182

All Works

Loading papers...

Rankless by CCL
2026